-

01:10:52 PM

SNOA Stock News

SNOA - Sonoma Pharmaceuticals Inc.

08/15/23 7:30 AM

Nasdaq : SNOA

low float

National Eczema Association Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced

BOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal

RHEA-AI

neutral

08/10/23 4:15 PM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports First Fiscal Quarter 2024 Financial Results

Revenue increased 6% in the first fiscal quarter compared to the same period last year, excluding a one-time event last yearMargins remained consistent year over year in an inflationary period, excluding the one-time eventSonoma continued to manage cash tightly, using only $0.3 million of cash in

RHEA-AI

negative

08/03/23 7:30 AM

Nasdaq : SNOA

managementlow float

Sonoma Pharmaceuticals Announces Appointment of Hye Jin Chung, M.D. to Scientific Advisory Board

BOULDER, CO / ACCESSWIRE / August 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal

RHEA-AI

positive

06/22/23 7:30 AM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2023 Financial Results

Revenues increased 31% in Q4 2023 compared to Q4 2022Revenues increased 5% in FY 2023 compared to FY 2022Net loss improved 56% quarter over quarterNet loss minus non-cash and one-time expenses decreased 65% quarter over quarter and 26% year over yearBOULDER, CO / ACCESSWIRE / June 22, 2023 / Sonoma

RHEA-AI

neutral

06/08/23 4:01 PM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

BOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, and

RHEA-AI

neutral

04/11/23 7:30 AM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care

RHEA-AI

very positive

03/28/23 4:15 PM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,

RHEA-AI

neutral

03/02/23 7:30 AM

Nasdaq : SNOA

low float

Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care,

RHEA-AI

neutral

02/14/23 4:30 PM

Nasdaq : SNOA

earningslow float

Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results

Cash burn of $717,000 for the quarter ended December 31, 2022, 68% less than prior quarter cash burn of $2,235,000 Revenues for three and nine months ended December 31, 2022 essentially flat with strong performance in international sales European revenues increased 51% for the quarter and 29% for

RHEA-AI

neutral

01/31/23 7:30 AM

Nasdaq : SNOA

partnershiplow float

Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea

Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal

RHEA-AI

very positive

SNOA Data

IndustryMedicinal and Botanical Manufacturing
Websitehttps://sonomapharma.com/
Security nameSonoma Pharmaceuticals Inc.
SectorManufacturing
Tags
- Health Technology
- Pharmaceuticals: Other
- Manufacturing
- Medicinal and Botanical Manufacturing
CountryUS

About Sonoma Pharmaceuticals Inc.

sonoma pharmaceuticals, inc., develops and produces stabilized hypochlorous acid (hocl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the united states and internationally. the company offers epicyn, an antimicrobial facial cleanser; levicyn, a hypochlorous acid (hocl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; sebuderm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and ceramax, a lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as loyon for the management of skin scal